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Atrial fibrillation (AF) is highly prevalent in patients with hypertrophic cardiomyopathy (HCM) and consti-
tutes one of the most common reasons for hospitalization.1 
There is a paucity of data on the effectiveness of rhythm 
control with antiarrhythmic agents in this patient population. 
Amiodarone represents the most studied one and is con-
sidered the drug of choice by current guidelines.2 Few data 
support the efficacy of sotalol or dofetilide in HCM patients 
with AF,3 as well as the antiarrhythmic effectiveness of diso-
pyramide, which has been shown to be safe when prescribed 
for control of left ventricular outflow tract obstruction.2,3 
Pulmonary vein antrum isolation (PVAI) has been recently 
reported as a feasible and safe therapeutic strategy in HCM 
patients with drug-refractory AF, with satisfactory short- and 
mid-term results.4–6 Thus far, scant data are available on the 
long-term results of PVAI in patients with HCM.4 In this 
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Background—Pulmonary vein (PV) antrum isolation in patients with hypertrophic cardiomyopathy and atrial fibrillation 
(AF) has been reported to have satisfactory results at the mid- and short-term follow-up. We determined the outcomes at 
the long-term follow-up of PV antrum isolation in these patients.
Methods and Results—We enrolled 43 patients with hypertrophic cardiomyopathy and AF (28% paroxysmal AF). PV 
antrum isolation (paroxysmal AF) and posterior wall isolation with complex fractionated atrial electrogram ablation 
(persistent and longstanding persistent AF) were the end points at the time of the index procedure and for repeat procedures 
during the first year of follow-up. In case of recurrent arrhythmia >1 year, high-dose isoproterenol challenge was used 
to disclose non-PV trigger sites. During the first year, the success rate reached 91% (mean of 1.6 procedures). After a 
median follow-up of 42 months (range, 38–48 months), 49% of the patients remained free from AF/atrial tachycardia. 
All patients underwent an additional procedure. PV antrum and posterior wall remained isolated in 82% of the cases, 
and extra-PV triggers were documented in all patients and targeted for ablation. After a median follow-up of 15 months 
(range, 8–19 months) subsequent to the last procedure, 94% of the patients remained free from AF/atrial tachycardia off 
antiarrhythmic drugs.
Conclusions—PV isolation in patients with hypertrophic cardiomyopathy is feasible and safe, although is not effective in 
preventing late (≥1 year) AF recurrences in ≈50% of patients. Non-PV triggers seem to be responsible of late recurrences, 
which supports the appropriateness of a more extensive ablation beyond PV isolation to improve the long-term arrhythmia-
free survival.  (Circ Arrhythm Electrophysiol. 2013;6:1089-1094.)
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study, we aimed to evaluate the long-term outcomes and the 
mechanisms of arrhythmia recurrence after radiofrequency 
catheter ablation of AF in patients with HCM to assess the 
optimal ablation strategy.
Methods
We included 43 consecutive patients (age, 59±8 years) with HCM and 
drug-refractory symptomatic AF. The diagnosis of HCM followed the 
American College of Cardiology/European Society of Cardiology 
guidelines.7 Definitions of paroxysmal, persistent, and longstanding 
persistent AF followed the American Heart Association/American 
College of Cardiology/European Society of Cardiology guide-
lines.8 Patients were in long-term treatment with therapeutic warfa-
rin, which was not discontinued during the periprocedural period.9 
Antiarrhythmic drugs were discontinued ≥5 half-lives before the pro-
cedure. Patients receiving amiodarone therapy discontinued the drug 
4 to 6 months before the ablation procedure. Informed consent was 
obtained from all patients, and all the data were entered in a central 
hub database approved by the Institutional Ethical Committee.
Instrumentation for Electrophysiological Study
Procedures were performed under either general anesthesia or con-
scious sedation. An esophageal probe was inserted in all patients 
to monitor esophageal temperature during ablation. Four venous 
 accesses were obtained: 2 in the right femoral vein, 1 in the left femo-
ral vein, and 1 in the right internal jugular vein. Right internal jugular 
vein access was used to place a 20-pole catheter in the coronary  sinus, 
with the proximal 10 poles positioned along the crista terminalis. The 
left femoral venous access was catheterized with an 11F venous sheath 
to insert a 10F 64-element phased-array ultrasound imaging catheter 
(intracardiac echocardiography [ICE]; AcuNav, Acuson, Mountain 
View, CA) in the right atrium under fluoroscopic guidance. A bolus of 
unfractionated heparin (10 000 U in men and 8000 U in women) was 
administered before the transseptal access, and intermittent infusion 
was adopted to maintain an activated clotting time >300 s. Left atrial 
access was obtained with a double transseptal puncture.
Catheter Ablation
Index Procedure and Repeat Procedures During the First 
Year of Follow-Up
Patients with paroxysmal AF underwent PVAI and isolation of the 
superior vena cava. The technique of PVAI has been described exten-
sively elsewhere.10 Briefly, a 3.5-mm irrigated-tip catheter (NaviStar 
ThermoCool; Biosense Webster, Diamond Bar, CA) and a circular 
mapping catheter (Lasso; Biosense Webster) were used. ICE was used 
to identify the PV antra to guide the positioning of the circular catheter 
and radiofrequency delivery and to look for all potential complications. 
Electroanatomic mapping was performed using the CARTO system 
(Biosense Webster, Diamond Bar, CA) or the EnSite NavX Navigation 
system (St Jude Medical, St Paul, MN). Radiofrequency energy was 
set at a power of 40 W (≤45 W) and at a catheter tip temperature of 
no more than 41°C. On the posterior wall, power was reduced to 35 
W; energy delivery was further reduced when the baseline esophageal 
temperature increased and was discontinued when the temperature 
reached 39°C. The end point of the procedures was elimination of all 
PV potentials along the antra with entry block. After isolation of all the 
PV antra and the posterior wall contained between the PVs, the circu-
lar mapping catheter was placed above the junction between the right 
atrium and superior vena cava at the level of the lower border of the 
pulmonary artery as imaged by ICE. Before radiofrequency delivery, 
maximum output pacing (≤20 mA) was performed at any site of the 
posterolateral side of the superior vena cava. If diaphragmatic stimula-
tion was present, ablation in this site was not performed to avoid injury 
to the phrenic nerve. The end point of ablation was to eliminate any 
potential along the mapping catheter (entry block).
In patients with persistent and longstanding persistent AF, the elec-
tric isolation of the PVs was extended to the entire posterior wall 
down to the coronary sinus and the left side of the septum.11
 Ablation 
of complex fractionated atrial electrograms in the left atrium and the 
coronary sinus was also performed.
If the AF organized into an atrial tachycardia, activation and entrain-
ment mapping were performed to attempt termination. Otherwise, 
patients were cardioverted after elimination of all complex fraction-
ated atrial electrogram sites. For recurrences occurring during the 
first year of follow-up, repeat procedures targeted only sites of recon-
nection around the PV antrum, posterior wall, interatrial septum, and 
coronary sinus. If patients presented with organized atrial arrhythmia 
(ie, atrial flutter/tachycardia), activation and entrainment mapping 
were performed to terminate the arrhythmia.
Repeat Procedures for Recurrences Beyond 1 Year  
(Late Recurrences)
For repeat procedures ≥1 year after the index procedure, in addition to 
the ablation strategy mentioned above (ie, ablation of sites of recon-
nection, mapping and ablation of organized atrial tachyarrhythmias), 
high doses of isoproterenol (20–30 μg/min) for 15 to 20 minutes were 
administrated to check for extra-PV firings (Figure 1), which were 
mapped as previously reported.12 No specific hemodynamic compro-
mise beyond that expected during isoproterenol test was encountered 
in this series of patients. The anesthesiologist participating in the pro-
cedure used phenylephrine to manage blood pressure decrease and 
allow the completion of the isoproterenol test. Non-PV triggers were 
defined either as consistent (≥10 in 1 minute) atrial premature depo-
larizations or as firing inducing AF/atrial tachyarrhythmia.
Follow-Up
The follow-up was performed at 3, 6, 9, 12, and then every 6 months 
after the procedure, with physical examination, 12-lead ECG, and 
7-day Holter monitoring. All patients received an event recorder for 
the first 5 months to record any symptomatic events. In addition, ran-
dom recordings were performed 2× to 3× per week to monitor for 
any asymptomatic episodes of AF. Recurrence was considered to be 
any episode of AF/atrial tachycardia lasting for ≥30 seconds after a 
blanking period of 3 months from the procedure. Repeat ablation was 
not allowed during the blanking period.
Late recurrence was defined as AF/atrial tachycardia recurrence oc-
curring beyond 1 year after the index procedure. Antiarrhythmic drugs 
(class III agents—sotalol or dofetilide in 41 cases, amiodarone in 2 
 cases) were systematically used for the blanking period and discontin-
ued after the end of the blanking period if patients were in sinus rhythm.
Statistical Analysis
Descriptive statistics are reported as mean±SD (or median and in-
terquartile range for skewed distributions) for continuous variables 
Figure 1. Study design and ablation strategy adopted in the 
study. AF indicates atrial fibrillation; CFAE, complex fractionated 
atrial electrograms; CS, coronary sinus; HCM, hypertrophic car-
diomyopathy; LA, left atrial; PV, pulmonary vein; PVAI, PV isola-
tion; PW, posterior wall; and SVC, superior vena cava.
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and as absolute frequencies and percentages for categorical variables. 
Between-group comparisons were performed with the unpaired 
Student t test for continuous data (Mann–Whitney U test when nor-
mality assumption was not possible) and with the Fisher exact for cat-
egorical variables. Long-term arrhythmia-free survival was reported 
as crude event rates and assessed through a time-to-event analysis by 
the Kaplan–Meier method. All tests were 2-sided, and a P<0.05 was 
considered statistically significant. To adjust for type I error while 
making multiple pairwise comparisons for the type of recurrent ar-
rhythmia in paroxysmal versus persistent and longstanding persistent 
AF populations, the P value for rejecting null hypothesis was set at 
a conservative level (P=0.01). Statistical analyses were performed by 
STATA version 11.1 (StataCorp, College Station, TX) software.
Results
The majority of patients had persistent (18 [41%]) and long-
standing persistent (13 [31%]) AF (Table). The mean left atrial 
diameter was 50.8±6.8 mm, and the left ventricular ejection 
fraction was 59±6%. Maximum left ventricular wall thickness 
was 19.8±3.9 mm. All patients had failed treatment with ≥1 
antiarrhythmic drug.
Index Procedure and First Year of Follow-Up
PVAI and isolation of the posterior wall between the PVs and 
of the superior vena cava were achieved in all patients with 
paroxysmal AF. In those with persistent and longstanding per-
sistent AF, ablation was extended to the entire posterior left 
atrial wall and to areas with complex fractionated atrial elec-
trograms in the left atrium and coronary sinus.13 The average 
radiofrequency time in patients with paroxysmal AF was 34±6 
minutes and was significantly longer in patients with persis-
tent and longstanding persistent AF (71±9 minutes; P<0.001 
for comparison with paroxysmal AF). The median fluoroscopy 
time was 49 minutes (range, 29–53 minutes), with a median 
procedural time of 176 minutes (range, 161–189 minutes).
All patients completed the follow-up monitoring, with all 
being compliant to the 7-day Holter monitoring. The compli-
ance to all the required transtelephonic transmission during 
the initial 5 months was ≈88%. At 1 year, the overall freedom 
from recurrent AF/atrial tachycardia after a single procedure 
was 53% (75% in patients with paroxysmal AF versus 45% in 
those with persistent and longstanding persistent AF; P=0.08 
for comparison), with most of the recurrences occurring 
between 3 and 9 months after the index procedure. Specifically, 
the recurrent arrhythmia was atypical atrial flutter in 65% of 
cases (69% in paroxysmal AF versus 71% in persistent and 
longstanding persistent AF; P>0.99) and AF in the remaining 
35% (33% in paroxysmal AF versus 29% in persistent and 
longstanding persistent AF; P>0.99). All patients with recur-
rence underwent repeat ablation (average 1.6±0.7 procedures 
[1–3]). Recovery of conduction across the previously targeted 
areas (most frequently in the PV antrum) was noted in all 
patients undergoing a repeat ablation; all areas demonstrat-
ing reconnection were reisolated during the repeat procedure 
(Figure 1). In patients presenting with atypical atrial flutter, 
repeat isolation of areas with reconnection always resulted in 
acute termination of the flutter. The overall secondary success 
rate at 1 year was 76% off antiarrhythmic drugs and reached 
91% including patients who were successfully treated with 
previously ineffective antiarrhythmic drugs. No major com-
plications occurred. Minor complications (minor hematoma 
at the femoral vein access sites) occurred in 2 (4.6%) patients.
Long-Term Follow-Up
After the first year of follow-up, an additional 18 patients 
experienced recurrent arrhythmia, with a cumulative success 
rate of 49% at a median follow-up of 42 months (range, 38–48 
months; Figure 2A). In particular, long-term arrhythmia-free 
survival was achieved in 67% of patients with paroxysmal AF, 
56% with persistent AF, and 23% with longstanding persistent 
AF (Figure 2B).
Most of the late recurrences occurred between 16 and 23 
months (Figure 2A and 2B), and all patients underwent an addi-
tional procedure (Figure 1). Atypical atrial flutter was the dom-
inant mode of recurrence in these patients, occurring in 89% 
of cases, whereas the remaining 11% presented with recurrent 
AF. Among the clinical variables, only type of AF was found to 
predict long-term success, with the highest risk of recurrence 
among patients with longstanding persistent AF (odds ratio, 
2.58; 95% confidence interval, 1.11–6.05; P=0.028).
Mechanism of Long-Term Recurrence, Ablation 
Strategy, and Outcomes
Persistent isolation of the previously targeted areas (ie, PV 
antra and posterior wall) was confirmed in 82% of patients. In 
the 16 patients presenting with atypical atrial flutter, activation 
and entrainment mapping were performed, and the arrhythmia 
was successfully terminated with ablation in 69% of cases. In 
the 2 patients presenting with recurrent AF, persistent isola-
tion of the previously targeted areas was confirmed at repeat 
ablation, and the patients were converted to sinus rhythm with 
Table.  Clinical Characteristics of the Patients Included in 
the Study
Variable N=43
Age, y 59±8
Sex, males 29 (67)
AF type
  Paroxysmal 12 (28)
  Persistent 18 (42)
  Longstanding persistent 13 (30)
NYHA functional class I 9 (21)
NYHA functional class II 31 (72)
NYHA functional class III 3 (7)
AF duration, mo (median, IQR) 36 (51)
LA diameter, mm 50.8±6.8
Maximum LV thickness, mm 19.8±3.9
LV ejection fraction, % 59±6
Implantable cardioverter-defibrillator 27 (63)
Failed antiarrhythmic drugs
  Amiodarone 36 (84)
  Sotalol 31 (72)
  Dofetilide 8 (19)
  Class IC agents 4 (9)
Values are expressed as mean±SD or n (%). AF indicates atrial fibrillation; 
IQR, interquartile range; LA, left atrial; LV, left ventricle; and NYHA, New York 
Heart Association.
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electric cardioversion. At high-dose isoproterenol challenge, 
non-PV sites of firing were detected in all patients. Non-PV 
triggers were most commonly mapped in the coronary sinus, 
left atrial appendage, interatrial septum, and right atrium/crista 
terminalis (Figure 3). Trigger ablation was performed with the 
aim of achieving electric isolation when triggers arose from 
the coronary sinus or left atrial appendage (LAA)  or with 
focal ablation in other areas, such as the interatrial septum 
and the crista terminalis. In these cases, the amount of abla-
tion increased by an average of 14±3 minutes for the coronary 
sinus (with the end point of complete isolation) or by an aver-
age of 31±4 minutes for achieving LAA isolation. No patient 
experienced any major complication, whereas 2 patients had 
a minor complication not requiring intervention (ie, 1 femo-
ral pseudoaneurysm, 1 groin hematoma). No clinical variable 
was found to significantly predict non-PV triggers, although 
patients with non-PV triggers were older (62±9 versus 57±7 
years; P=0.07), had larger left atrial diameters (52±7 mm ver-
sus 49±6 mm; P=0.29), and had lower left ventricular ejection 
fraction (58±5% versus 61±6%; P=0.08). At a median follow-
up of 15 months (range, 8–19 months) after the last procedure, 
94% of the patients remained free from AF/atrial tachycardia 
off antiarrhythmic drugs.
Discussion
The present study reports the results of catheter ablation of 
AF in a large series of patients with HCM, with the longest 
follow-up to date. The major findings are as follows: (1) 
catheter ablation of AF in patients with HCM is a safe and 
effective approach to achieve long-term freedom from recur-
rent arrhythmia; (2) PV and posterior wall isolation alone 
are insufficient to obtain satisfactory long-term results even 
when permanent isolation is achieved; (3) non-PV triggers can 
be demonstrated in the majority of HCM patients with late 
arrhythmia recurrence; and (4) ablation of non-PV triggers is 
associated with a significant improvement in the long-term 
arrhythmia-free survival.
AF has a major effect on morbidity and mortality in patients 
with HCM.14 Radiofrequency catheter ablation has been pro-
posed as an effective rhythm-control treatment for HCM 
patients with AF.4,6,15 Specifically, PV antrum isolation (with 
or without additional left atrial linear ablation)4–6,15 has shown 
satisfactory results at mid-term follow-up. The present study 
shows that the benefit of PV antrum and posterior wall isola-
tion is limited at the long-term follow-up, even when persis-
tent isolation is achieved. Rather, non-PV triggers seem highly 
prevalent in these patients. These results support the concept 
Figure 3. Electrophysiological findings at 
repeat procedures in patients presenting 
with late (≥1 year) atrial arrhythmia recur-
rence. PV indicates pulmonary vein.
Figure 2. A, Kaplan–Meier survival curve showing multiple-
procedure freedom from any atrial arrhythmia recurrence after 
pulmonary vein (PV) and posterior wall isolation (without abla-
tion of non-PV triggers). B, Kaplan–Meier survival curve showing 
multiple-procedure freedom from any atrial arrhythmia recurrence 
after PV and posterior wall isolation (without ablation of non-PV 
triggers) according to the type of presenting atrial fibrillation (AF). 
Time zero is the last ablation targeting the PV and posterior wall 
without non-PV trigger ablation. AT indicates atrial tachycardia.
 by guest on D
ecem
ber 28, 2017
http://circep.ahajournals.org/
D
ow
nloaded from
 
Santangeli et al  Catheter Ablation of AF in Hypertrophic Cardiomyopathy  1093
that HCM patients with AF represent a specific population 
in whom PV isolation alone should not be considered suffi-
cient as a stand-alone approach, and a more extensive abla-
tion beyond the PV antrum and posterior wall is necessary to 
increase the long-term arrhythmia-free survival.
From a pathophysiological perspective, the effect of 
chronic atrial stretch because of diastolic dysfunction lead-
ing to diffuse atrial fibrosis,16 the presence of mitral regur-
gitation caused by systolic anterior motion of the mitral 
valve, and the underlying atrial myopathy caused by the 
sarcomere protein gene mutations14 might provide the sub-
strate for multiple arrhythmogenic areas beyond the PVs 
in such patients. Previous studies evaluating the role of PV 
isolation in patients with HCM have shown that enlarged 
left atria, increasing age, and more advanced heart failure 
symptoms are predictors of arrhythmia recurrence after PV 
isolation4; the presence and role of non-PV triggers were 
not investigated in such studies, and the electrophysiologi-
cal mechanisms underlying the lack of clinical response to 
PV isolation during follow-up remained undefined. Non-PV 
triggers could provide an explanation for the lack of sus-
tained response to PV isolation shown in previous studies4 
because older age,17 enlarged left atria,18 and more advanced 
heart failure19 have all been linked to a higher prevalence of 
non-PV triggers.
The present study also allows to draw clinically relevant 
conclusions on the optimal ablation strategy in these patients 
by showing that non-PV trigger ablation is associated with a 
significant arrhythmia-free survival benefit. More than 90% 
of patients were free from any recurrent arrhythmia without 
antiarrhythmic medications at an average of 14 months after 
the last procedure. The majority of patients with late arrhyth-
mia recurrence presented with atypical atrial flutter, which 
was successfully mapped and ablated in approximately two 
thirds of cases. Flutter termination was not found to predict 
the long-term outcome in our patient cohort (P=0.49); again, 
trigger ablation seemed to be the only reliable predictor of 
success. These findings are in line with the concept that 
postablation-organized reentrant arrhythmias are the conse-
quence of spontaneous triggering from specific structures, 
such as the PV, the coronary sinus, the LAA or the interatrial 
septum/right atrium.20
Study Limitations
This study had a prospective nonrandomized design and 
included a relatively small sample of patients. The presence 
of non-PV triggers was not assessed at the time of the index 
procedure and for repeat procedures during the first year of 
follow-up because of concerns of inducing or worsening intra-
ventricular obstruction during isoproterenol test. However, no 
complications were observed during high-dose isoproterenol 
test at repeat procedures beyond 1 year, thus suggesting that 
isoproterenol challenge is safe in these patients, albeit we did 
not actively assess the presence of a dynamic gradient during 
the isoproterenol challenge. In addition, we could not evalu-
ate whether non-PV triggers were already present at the time 
of the first ablation or only represented a late phenomenon 
responsible for arrhythmia recurrence at long-term follow-
up. The lack of assessment for PV exit block might represent 
another limitation. Most of the late recurrences were observed 
between 16 and 23 months after the index procedure, which 
might be explained by the fact that most of the follow-up 
beyond 1 year occurred within that time frame. It is possi-
ble that, if the follow-up was longer, more late recurrences 
might be seen. Finally, assessment of the left atrial function 
after ablation was not an end point of the study and was per-
formed only in patients undergoing extensive anterior abla-
tion, including isolation of the LAA.
Conclusions
PV isolation in patients with HCM is feasible and safe, 
although is not effective in preventing late (≥1 year) AF 
recurrences in ≈50% of patients. Non-PV triggers seem to 
be responsible for late recurrences in the majority of these 
patients. This supports the appropriateness of a more exten-
sive ablation strategy targeting multiple structures other than 
the PV antra to improve long-term success.
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CLINICAL PERSPECTIVE
Pulmonary vein antrum (PVA) isolation has been reported as a feasible and safe treatment for patients with hypertrophic car-
diomyopathy and atrial fibrillation (AF), with satisfactory short- and mid-term results. The long-term outcomes of PVA iso-
lation in this subset of patients are still poorly defined. The present study evaluated the long-term outcomes and mechanisms 
of arrhythmia recurrence in a consecutive series of 43 patients with hypertrophic cardiomyopathy and AF. PVA isolation 
(paroxysmal AF) and posterior wall isolation with complex fractionated atrial electrogram ablation (non–paroxysmal AF) 
were the end points at the time of the index procedure and for repeat procedures during the first year of follow-up. With such 
an ablation strategy, freedom from recurrent AF/atrial tachycardia was achieved in 49% of the cases after a median follow-up 
of 42 months. High-dose isoproterenol challenge was used to disclose non-PV trigger sites for patients presenting with recur-
rent arrhythmia beyond 1 year from the index procedure. Persistent isolation of the PVA and posterior wall was documented 
in 82% of patients, and extra-PV triggers were found in all cases and targeted for ablation. After a median follow-up of 15 
months after the last procedure, 94% of the patients remained free from AF/atrial tachycardia off antiarrhythmic drugs. The 
results of this study highlight that PVA isolation has suboptimal long-term results in patients with hypertrophic cardiomy-
opathy, possibly because of a high incidence of non-PV triggers that are responsible for late arrhythmia recurrence.
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